Alzheon CEO Martin Tolar interview with BNN Bloomberg, Canada’s Business News Network reporting on finance and the markets
Listen to our CEO Martin Tolar discuss key learnings from the Aducanumab FDA advisory committee, how agents which target the key toxin – soluble oligomers have reshaped the Alzheimer’s treatment landscape, and why Alzheon’s oral tablet ALZ-801 has potential to become the first effective disease-modifying agent.
“The real breakthrough is that after 2 decades of failure, we finally know what the right target is… we have a product that’s oral, safe and could eventually be used preventatively…and change the course of the disease” said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon.
Use the outline below to jump to the answers you want to hear within this video interview:
What is the platform you are using, what makes it different and how is it similar or different from what Biogen is up to? [00:43 ]
Where are you (Alzheon) in the path? [02:27]
Can you give some context to the Biogen FDA Advisory Committee meeting? [03:30]
What does success look like? What stage are patients at and what sort of resolution or improvement, that you see, that measures success for your drug? [05:40]
